Adenylate cyclase in liver plasma membranes from streptozotocin-diabetic (STZ) or BB/Wor spontaneously diabetic rats showed increased responsiveness to GTP, glucagon, fluoroalu_inate, and cholera toxin. Basal or forskolin-stimulated activity was unchanged in STZ rats, but increased in BB/Wor rats.
Introduction
In experimental and naturally occurring forms of diabetes mellitus, the production of glucose, fatty acids, and ketone bodies exceeds their utilization, resulting in many of the features characteristic of the disease. There is considerable evidence that hyperglucagonemia and the resulting increases in hepatic glycogenolysis, gluconeogenesis, and ketogenesis are causal factors in some ofthese changes (see 1, 2 for review). In rats, these changes are associated with an increase in hepatic cAMP content (3) (4) (5) (6) in both experimental diabetes (e.g., induced by exogenous insulin-antibodies, alloxan or streptozo- 1 . Abbreviations used in this paper: BB/Wor, Bio-Breeding Worcester rat; DB-RES, diabetes-resistant rat; G-protein, guanine nucleotide binding regulatory protein; Gi, inhibitory guanine nucleotide binding protein of adenylate cyclase; G., a G protein of unknown function (e.g., the spontaneously diabetic Bio-Breeding Worcester rat LBB/Wor]). Since it is commonly found that desensitization occurs when cells are exposed to elevated levels of hormones such as glucagon (e.g., 7) this increase in hepatic cAMP in diabetes is surprising.
There are many proteins involved in regulating hepatic cAMP production. These include the glucagon and ,32-adrenergic stimulatory receptors, the a2-adrenergic and angiotensin II inhibitory receptors, the stimulatory (G,) and inhibitory (G1) guanine nucleotide binding proteins, the adenylate cyclase catalytic moiety, and cAMP phosphodiesterase. In theory, the increased hepatic cAMP in diabetes could be due to changes in one or more of these proteins. Alternatively, if no changes occurred in this system, the mere increase in the plasma concentration ratio of glucagon to insulin in diabetes could explain the increase in hepatic cAMP in this disease. Several groups have explored the possibility that molecular components of the adenylate cyclase system are altered in diabetic liver by studying glucagon receptor binding and/or adenylate cyclase activity in liver cells and plasma membranes from normal and STZ-diabetic rats (5, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . However, the results of these studies have been confficting. For example, glucagon-sensitive and basal adenylate cyclase activities have been reported to be either increased, decreased, or unchanged in liver plasma membranes from STZ-diabetic rats (5, 10, 12, (14) (15) (16) (17) (18) . In addition, several groups have reported that STZ treatment decreases plasma membrane marker enzymes in liver homogenates and/or membrane preparations (13, 14, 17, 18) . While this has not been a consistent finding (5, 15) , it may explain why some have observed decreases in total hepatic adenylate cyclase activity and glucagon receptor binding and Gi in chemically induced diabetes. The hepatotoxicity of some diabetogenic agents may also partly account for the differences (for review see 19) . Another possible source ofvariability is the severity ofthe diabetic state, which varies with route ofadministration and dose of streptozotocin or alloxan. Obviously these variables are not a problem in the naturally occurring form of diabetes exhibited by BB/Wor rats (for review see compared several of these parameters in animals whose hepatic Gi function has been inactivated by islet-activating pertussis toxin (TAP). Because ofthe problems inherent in the use of the STZ-model (see above) we have also examined these parameters, for the first time, in the spontaneously diabetic rat (BB/Wor) and its genetic counterpart the diabetic-resistant rat (DB-RES).
Our data indicate that increased expression ofG, may contribute to the increase in hepatic cAMP in the acute STZ-diabetic and spontaneously diabetic BB/Wor rat. Additionally, unlike STZ-diabetes, the naturally occurring form of diabetes exhibited by the BB/Wor rats is associated with an approximately twofold increase in basal and forskolin-stimulated hepatic adenylate cyclase activity. Thus insulin may regulate the expression of regulatory and catalytic components of the adenylate cyclase system.
Methods
Materials.
[32P]NAD (1, 000 Ci/mmol) and [a-32P]ATP (3,000 Ci/ mmol) were from New England Nuclear (Boston, MA). S49 cyc-(94.15.1) cells were obtained from the Cell Culture Facility of the University of California, San Francisco. Acute spontaneously diabetic (BB/Wor) rats and their diabetic resistant counterparts (DB-RES) were obtained from Dr. Dennis L. Guberski (Department of Pathology, University of Massachusetts Medical School, Worcester, MA). At the University of Massachusetts, the urine of BB/Wor rats was analyzed twice a week to detect diabetes of spontaneous onset (termed conversion). After detection of conversion, the animals were monitored daily and stabilized by insulin injection to maintain a moderate diabetic state (i.e., +4 urine glucose and 0 ketones). Insulin doses were individualized and ranged from 1.4 to 2.6 U/d in rats weighing between 180 and 350 g. Animals were received 1-6 d after detection of conversion and were used immediately along with their DB-RES counterparts, which served as controls for BB/Wor in this study. Glucagon, insulin, and protamine zinc insulin suspension were from Eli Lilly (Indianapolis, IN). NaF and AIC13 were from Fisher Scientific Co. (Pittsburgh, PA Abolition of G1 activity was obtained 24 h after intraperitoneal injection of IAP (25 mg/ 100 g body wt) as previously described (22).
Plasma membrane purification, hepatocyte isolation and cAMP measurement. Experimental treatment groups (i.e., control, diabetic, insulin-replaced) typically consisted of five animals (with the exception of IAP-treated groups which consisted of 1-2 animals per group). One or two of these animals were used for hepatocyte studies and the remainder were used for plasma membrane preparation. Liver plasma membranes prepared by Percoll density gradient centrifugation (26) were resuspended in 25 mM Tris HC1 and 1 mM EGTA (pH 7.4), and then frozen in liquid N2 for storage at -70°C. Membranes from control and experimental groups were prepared on the same day. Membrane protein was determined using BCA assay (Pierce Chemical Co., Rockford, IL).
Liver parenchymal cells from control and diabetic rats were prepared (24) simultaneously and cAMP measurements were carried out as described elsewhere (27) .
Adenylate cyclase activity. The method of Salomon (28) was used to assay adenylate cyclase in liver plasma membranes. The assay was performed at 30'C in a final volume of 50 ul for 10-15 min with the following components: 0.5 mM [a-32P]ATP (70-150 cpm/pmol), 20 mM creatine phosphate, 50 U/ml creatine phosphokinase, 25 mM Tris HCl (pH 7.4), 5 mM magnesium acetate, 0.05 mM cAMP, 1 mM DTT, 0.1 mg/ml BSA, 0.9-1.5 mg membrane protein/ml and other additives as indicated. Activity measured in the absence of other additives is termed basal activity. The assay was initiated by the addition of membranes and terminated by the addition of 100 ml of medium (pH 7.5) containing 2% SDS, 45 mM ATP, and 1.3 mM cAMP. Addition of [3H]cAMP for the estimation of [32P]cAMP recovery preceded boiling for 5 min and column purification as described by Salomon (28) . Radioactive content was determined using a Beckman LS3801 scintillation counter. Results shown are representative of two to six experiments on different membrane batches.
Bacterial toxin catalyzed [32PADP incorporation into Gs and Gi. IAP-catalyzed [32P]ADP incorporation into plasma membrane Gi has been described (22). In some experiments cholate-solubilized hepatocyte proteins were used as substrate in place of plasma membranes. For this purpose hepatocytes from control or diabetic animals were adjusted to equal wet weights (-30-40 mg/ml) and 1 ml of suspended cells was centrifuged at 11,000 g for 1 min. The cell pellet was solubilized in 0.5 ml of 1% sodium cholate (pH 8.0), 1 mM EDTA, and 1 mM DTT. Unsolubilized material was removed by centrifugation at 100,000 g for 1 h at 4°C. Assayed proteins were precipitated with TCA as described above. Precipitated proteins from the cholera toxin and IAP studies were solubilized for SDS-PAGE, and autoradiography of the dried gels was performed as described previously (22, 30) . Quantitation of radioactivity incorporated into peptides was determined by scintillation spectrometry or by laser densitometry of autoradiographs and computer integration of the peaks.
S49 cyc assayfor G, activity. G, activity was determined by measuring the ability of 1% cholate solubilized liver membranes (1.5 mg/ml) to stimulate MgATP-dependent adenylate cyclase activity in plasma membranes from S49 cyc-lymphoma cells, which lack endogenous G, (31) (32) (33) . Briefly, S49 cyc-lymphoma cells were harvested and plasma membranes prepared by the method of Ross et al. (34) .
The adenylate cyclase reconstitution assay for G, activity used was an adaptation of the method of Sternweis et al. (35) . Cholate solubilized liver plasma membranes (60 ,l) were incubated with 25 Mi of AMF for 10 min at 0°C. AMF consists of ATP (I mM), MgCl2 (10 mM), NaF (10 mM), and AlCl3 (0.25 mM). Subsequently, 15 Ml of this mixture was mixed with 25 ,gl ofcyc-plasma membranes on ice and allowed to isobutylmethylxanthine (0.25 mM), NaF (10 mM), AlCl3 (0.25 mM), potassium phosphoenolpyruvate (7.5 mM), and pyruvate kinase (25 ug/ml). The reaction was terminated and cyclic AMP quantitated as described above for adenylate cyclase (28) . Antiserum production. In initial studies antisera were raised to synthetic peptides corresponding to internal sequences of several G protein a-subunits including the peptide termed "a-common" (36) . How (38, 40) , ao (38, 40) , aT (41), ai-1, and ai-2 (38, 39 Basal and forskolin-sensitive adenylate cyclase activity. Table II shows that adenylate cyclase activity in response to 100 ,uM forskolin was not significantly different between control and STZ-diabetic animals (cf. 14, 16) . In agreement with this finding, basal activity was also not altered by STZ-diabetes (Table TI) . Further, no difference was observed when adenylate cyclase was assayed in the presence of ATP and Mn2+, which may be a more accurate reflection of the catalytic component per se (Table III) . In contrast both basal and forskolin-sensitive adenylate cyclase were elevated in acute diabetic BB/Wor-diabetic animals as compared to DB-RES (Tables II and III) .
GTP and glucagon stimulation of adenylate cyclase. Neither streptozotocin-or IAP-treatment caused any significant effect on the EC50 for GTP ( Fig. 1 ) and GTPyS (data not shown) stimulation of adenylate cyclase activity. However, maximal and submaximal concentrations of these guanine nucleotides elicited greater adenylate cyclase activity in membranes from animals receiving either treatment. The increases in a series of experiments (50-100 ,uM nucleotide) were smaller in membranes from STZ-treated rats (133±7% of control, n = 15 animals, P < 0.05, t test) than in membranes from TAP-treated rats (196±20% of control, n = 3 animals, P < 0.05, t test).
GTP-sensitive adenylate cyclase activity was also increased in BB/Wor rats ( Fig. 1 ) relative to DB-RES, although no effect was observed on the EC50 for this compound. The magnitude ofthe increase in GTP-sensitive adenylate cyclase (50-100 gM GTP) activity observed in the BB/Wor-diabetics was larger than the increase in basal activity in a series of experiments (i.e., 210±12% forGTP vs. 166±17% forbasal, P < 0.05, ttest) and therefore may not be due just to a change in adenylate cyclase per se. Fig. 2 shows that neither STZ-nor IAP-treatment affected the EC50 for glucagon activation of adenylate cyclase, which ranged from 3 to 10 nM in four different experiments. However, as with GTP, glucagon responses (measured in the presence of 50 ,uM GTP) were larger in membranes from IAPtreated and STZ-diabetic animals. In the absence of GTP, the glucagon response was greatly reduced (15) . The 2 also shows that hepatic adenylate cyclase of BB/ Wor-diabetic rats showed increased responsiveness to glucagon relative to DB-RES rats (238±12% for 100 nM glucagon from five determinations, P < 0.05, t test). In agreement with the findings with the STZ model, in BB/Wor-diabetic membranes, the glucagon (plus GTP) responses were also significantly higher than the responses to GTP alone (238±12% vs. 210±12%, respectively) and no effect was observed on the EC50 for glucagon which ranged from 2 to 5 nM in these animals.
Fluoroaluminate and cholera toxin A-subunit stimulation of adenylate cyclase activity. In Fig. 3 , the effects of NaF on adenylate cyclase were measured in the presence of 250 ,M In contrast, membranes from STZ-diabetic animals exhib ited elevated adenylate cyclase activity in response to all concentrations of NaF tested (Fig. 3) . BB/Wor-diabetic rats also showed increased responsiveness to fluoroaluminate compared with DB-RES. The extent of this increase was larger at submaximal (e.g., from 299 to 361%) than at maximal concentrations of NaF (e.g., 211-244%). Fig. 4 shows the concentration-dependent stimulation of adenylate cyclase by the A-subunit of cholera toxin. These experiments were performed in the presence of sodium phosphate, GTP, and NAD. Sodium phosphate is necessary for optimal modification of G, by cholera toxin (29) , but has inhibitory effects on adenylate cyclase. For this reason a lower, less inhibitory, concentration of sodium phosphate (100 mM) was employed in these studies, as compared to 400 mM used in [32P]ADP ribosylation experiments. As compared to control, membranes from STZ-diabetic animals displayed an increased response to every concentration of cholera toxin Asubunit tested (Fig. 4, Table IV ). In agreement with the findings with GTP and glucagon, cholera toxin produced even greater increases in membranes from IAP-treated rats (Fig. 4) . The effect of STZ-diabetes on cholera toxin-stimulated adenylate cyclase activity could be partly reversed by insulin replacement (Table IV) supporting the idea that this effect is due to loss of insulin. Sodium phosphate and NAD reduced the elevation in BB/Wor hepatic adenylate cyclase typically observed in the presence of GTP alone (from 166±16% to 128±4% above the activity observed in DB-RES). This was increased to 170-180% above the DB-RES controls in the presence of all concentrations of cholera toxin A-subunit tested (Fig. 4) . Thus the changes in fluoroaluminate-and cholera toxin-as well as GTP-and glucagon-stimulated activities were in excess of the increases in basal cyclase activity of the BB/Wor rat.
Angiotensin II inhibition ofadenylate cyclase activity and ofcellular cAMP content. Angiotensin II inhibition of adenylate cyclase activity has been used as a measure of G1 function in liver membranes (46 Insulin-replaced* 4 1,734±85 113±5 * Adenylate cyclase activity was measured in the presence of 70 mg/ml of cholera toxin A subunit and other additives as described in Fig. 2 (Fig. 5) was observed, although as expected, this effect was attenuated in membranes from IAP-treated nondiabetic rats. In agreement with the membrane studies (Fig. 5) , neither form of diabetes had any significant effect on the ability of angiotensin IT to lower glucagon-elevated cAMP levels in hepatocytes (Fig. 6) . In summary, the results of the adenylate cyclase experiments (Figs. 1-6 , Tables I-III) were more consistent with an increase in G, activity in STZ-diabetes or an increase in the catalytic activity of adenylate cyclase and in G, activity in BB/Wor-diabetes rather than a physiologically important loss of Gi.
IAP-and cholera toxin-catalyzed [32P]ADP ribosylation of G, and Gi. The incorporation of 32p into Gi or G, stimulated by repetitive addition of [32PJNAD in the presence of IAP or cholera toxin A subunit under conditions optimized for either toxin was used as an index of the levels of Gi and G, in liver membranes. Fig. 7 (A) shows that, as previously reported (22), IAP-treatment resulted in a > 97% reduction of labeling of a 41-kD peptide in Sprague-Dawley rat liver plasma membranes, (presumably one or more species of ai). Fig. 7 (A) also shows that radiolabeling of Gi was not significantly different in membranes from STZ-diabetic animals (i.e., 104±8% when compared to control, n = 5 separate batches of membranes To enhance the effect of angiotensin II on GTP-stimulated adenylate cyclase activity, 1 ml of frozen liver plasma membranes (3-4 mg/ml) were thawed and resuspended in 14 ml of medium containing 10 mM Tris HCl, 5 mM EDTA and 0.05% j3-mercaptoethanol (46, 48, 49) . Membranes were adjusted to from diabetic animals). Similarly, no change was observed in
Gi radiolabeling in cholate-solubilized hepatocytes prepared from diabetic rats (Fig. 7 A) . In contrast, a 40±8% average decrease was observed in Gi radiolabeling in nine separate batches of liver membranes from BB/Wor-diabetic rats relative to DB-RES rats (Fig. 7 B) (Fig. 8, top) . The increase in the radiolabeling was the same for both peptides and ranged from 125 to 200% in a series of experiments (n = 7 separate membrane batches). This effect could be partly reversed by insulin replacement (Table V) . A significant increase was also observed in the radiolabeling of these peptides in membranes from BB/ Wor rats (Fig. 8, bottom) , however the extent of the increase was not the same for both peptides (i.e., 153±6% vs. 120±5% increase in the 43-and 47.5-kD peptides respectively, n = 4 separate membrane batches). Heyworth and co-workers (49) Immunological studies We synthesized peptides containing sequences corresponding to the C-terminal decapeptides of several G-protein a-subunits including ai1, ai-2, and ai3 (38, 39) , aT (41), a. (38, 40) , and a. (38, 40 mocyanin (44) were raised in rabbits as described in Methods. This approach has been used for a number of G-proteins (16, 36, 37, 52 ). Fig. 9 shows the peptide specificity and immunoreactivity of antisera prepared against four of these peptides ai3, ao, as, and aT. Antiserum 940, prepared against the ai-3 peptide showed similar reactivity, at dilutions of 1/100 or less, toward all of the peptides except a,. At greater dilutions, antiserum 940 was less effective at recognizing aT, a0, and aijl,2(argan) peptides compared to ai-3, ai-3<ser) and ai-1,2 (Fig. 9 A) . Antiserum 939, prepared against the aT peptide [identical to the peptide employed by Gawler et al. (16) ] displayed a broad range of reactivities. The order of immunoreactivity for this antiserum, at dilutions of 1/100 to 1/1,000, against the various peptides tested was ai-1,2(amasn) > aT 2 a04-1,2> ai-3> ai-3(ser) > ao > as (Fig. 9 B) . The poor reactivity ofthis antiserum to G0 is in agreement with the findings of Gawler et al. (16) using antiserum AS/7. However as exemplified by antiserum 918 * [32PJADP ribosylation in the presence of cholera toxin A subunit was performed as described in Methods. The 43-47.5 kD regions of the polyacrylamide gels were excised and the radioactivity measured by scintillation spectrometry. The mean of the distribution underlying the STZ-diabetic values from the three experiments shown is greater than that of control as determined by Student's t test (two samples with paired observations, P < 0.05). In contrast the insulinreplaced values were not found to be significantly different from control, P > 0.05).
Insulin replacement was performed as described in Table IV legend.
( Fig. 9 C) antiserum raised against the a. peptide was highly specific for this peptide relative to the others. Antiserum 929 raised against peptide ao produced a weak reaction that was relatively specific for the a., aj-3, and ai-3(ser), but not the other peptides (Fig. 9 D) .4 Fig. 10 shows the reaction ofthese antisera and preimmune serum with liver plasma membrane proteins separated by SDS-PAGE. Anti-aO serum and preimmune serum did not react significantly in immunoblots with any proteins in the 38-49-kD range. The negative finding with anti-aO serum is in agreement with studies indicating that G. is poorly expressed in liver (37, 53, 54) . In contrast, anti-ai-3 and anti-aT sera showed strong reactivity towards a 41-kD protein. This was also true for anti-ai_1,2 and anti-aI-3(ser) sera, whereas anti-ai-1,2(argasn) serum recognized many proteins (all data not shown). There was also some reaction of the anti-aT serum with proteins in the 45-48-kD range (Fig. 10) , however this was inconsistently observed (e.g., Fig. 1 1) . The anti-a. serum reacted with two proteins of 43-and 47.5-kD weight (Fig. 10) . These correspond to the two cholera toxin substrates found in rat liver plasma membranes and are presumed to be two species of a,.
We observed no significant change in the level ofthe 41-kD protein detected by anti-aT and anti-ai-3 sera in membranes from either STZ-diabetic rats (three different membrane batch preparations) or BB/Wor diabetic rats (five different mem-4. We also raised peptide antisera to other regions of G,, Go,,, and
Gi.a2, and to a sequence common to many G-protein a-subunits (36, 37) . However, in agreement with Mumby et al. (37) , these crossreacted too weakly with the rat liver plasma membrane proteins to be useful in quantitating the G-proteins. brane batch preparations) compared to the appropriate controls ( Fig. 1 1) . This was not due to limitations in quantitation since the amount of 41 kD protein detected was shown to be proportional to the amount of membrane protein loaded on to the gels (data not shown). These findings differ from those of Gawler et al. (16) , who observed nearly complete loss of immunoreactivity to anti-aT sera in STZ-diabetic rats (16) . In contrast, immunoreactivity ofthe anti-a, sera with the 43-and 47.5-kD regions of immunoblots was increased 145±12% and 162±20% in STZ-and BB/Wor-diabetic rats, respectively, compared to controls as determined by laser densitometry (Fig. 1 1) . This supports the conclusion that G, levels are increased in diabetic rat liver.
Discussion
Several groups have explored the possibility that the hepatic adenylate cyclase system is altered in diabetes (5, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Such an alteration seems likely since naturally occurring and experimental diabetes in rats have consistently been associated with an increase in hepatic cAMP content (3) (4) (5) (6) . In order to investigate this problem, most groups have used the streptozotocin model of diabetes. Unfortunately, the results from these studies have been inconsistent. For example, it has been reported that glucagon receptor binding capacity in liver membranes or cells is either unchanged (9-11) or decreased (12-14) by experimental diabetes. Basal and glucagon-stimulated hepatic adenylate cyclase activity has been found to be either increased, decreased, or unchanged in STZdiabetes (5, 10, 12, (14) (15) (16) (17) (18) . Furthermore, GTP-sensitive adenylate cyclase or Gr-activity has been reported to be either .0
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Serum dilution factor Figure 9 . Specificity of antisera for various peptides. Each increased (15) or decreased (14) . Alternatively, Gawler et al. (16) have provided evidence that Gi is abolished in both alloxan-and STZ-injected diabetic animals. One explanation for some of these discrepancies comes from the observation that STZ-treatment can decrease plasma membrane markers in liver homogenates and/or plasma membrane preparations (13, 14, 17, 18) , although this too has been an inconsistent finding Antisera no. (Table I and references 5, 15). Another possible explanation for some of these inconsistencies is that the severity of the diabetic state varies with the dose and route of administration of diabetogenic agents. The hepatoxicity of this class of compounds may also account for some these differences (see 19 for review).
In this study we sought to overcome these variables by examining the roles ofG5, G., and hepatic adenylate cyclase in both the STZ and BB/Wor-diabetes models. The BB/Wor model is a naturally occurring form of diabetes which is not subject to the problems inherent to the STZ model and may be more relevant to insulin-dependent diabetes mellitus in humans (for review see 20, 21).
STZ-diabetes. Since previous studies have not revealed increases in glucagon receptor number in liver cells or in liver membranes from diabetic animals (9-14), we hypothesized that the changes in hepatic cAMP content in STZ-diabetes (3-5) might be due to changes in the expression or activity of adenylate cyclase or of the G-proteins G( and Gi, which regulate the activity of this enzyme. To differentiate between these possibilities we studied the effects ofGTP, glucagon, forskolin, fluoroaluminate, cholera toxin, and IAP on adenylate cyclase activity.
A possible explanation of the increased adenylate cyclase responsiveness in the diabetic state is an increase in the catalytic activity of the enzyme. This appears unlikely for the STZ-diabetic rats, since there were no changes in basal (Figs. 1,  3 , and Table II) or forskolin-stimulated (Table II) adenylate cyclase activity in these animals.
Another explanation is that the plasma membrane purification procedure leads to a greater enrichment of these membranes in the preparations from diabetic animals. However, we observed no significant change in the levels of plasma membrane markers, e.g., 5'nucleotidase activity, in the preparations from STZ-diabetic rats (Table I , references 5, 15; cf. 13, 14, 17, 18). Dighe et al. (14) reported that the loss of plasma membrane markers varied with the dose ofSTZ and presumably the severity of the diabetic state. While our animals were clearly diabetic (i.e., urine glucoses > 200 mg/dl and serum glucoses > 400 mg/dl), the diabetes may not have been severe enough to cause changes in 5'-nucleotidase and other membrane markers.2
Several differences were noted between the effects of IAPtreatment and STZ-diabetes on adenylate cyclase. Plasma membranes from both groups displayed an increased responsiveness to GTP, glucagon, and cholera toxin A subunit (Figs.  1, 2, 4) . However, the increase was much larger in lAP-treated membranes. These results per se are consistent with the view that Gi activity is decreased though not abolished in diabetes (cf. 16 ). However, a number of findings do not support this conclusion as follows: (a) Angiotensin II inhibition of cAMP formation in membranes and of glucagon-elevated cAMP content in cells was not impaired by diabetes (Figs. 5-6 (Fig. 7) . (c) We also detected no change in Gi when this was measured immunologically (Fig. 11) .
This latter result is discrepant with that of Gawler et al. (16) , even though identical treatment protocols were employed, including dose of streptozotocin, treatment time, as well as species, strain, sex, and weight of the rats. We also consistently observed that diabetes did not alter basal adenylate cyclase activity, whereas they observed a 45-50% decrease which was not reversed by insulin treatment (cf. 14). We also found a greater maximal cyclase activity with glucagon in the diabetic membranes compared with the control membranes, whereas they observed the same maximal activity.
In the study of Gawler et al. (16) immunoblotting of crude rat liver plasma membranes with antiserum to the COOH-terminal decapeptide of aT was performed to measure the a-subunit ofGi. In our study, we utilized antisera raised against this peptide and also the COOH-terminal decapeptide of Gia_3.
Neither antiserum detected a difference in the Gia content of purified liver plasma membranes from STZ rats (Fig. 1 1) . We also employed IAP-stimulated ADP-ribosylation of purified liver membranes to measure Gi. (Fig. 8 ) the increase in cyc-reconstitutable Gr-activity (Table VI) and the increase in immunoreactivity of 43-and 47.5-kD proteins (presumed to be Gs a subunits) against antiserum raised to the COOH-terminal peptide of rat brain Gsa (Fig. 1 1) . The ADP-ribosylation and the increased responsiveness of adenylate cyclase to cholera toxin A-subunit, were reversed by insulin therapy (Tables  III and IV ). An elevation of Gs is also consistent with all the hepatic adenylate cyclase data (Figs. 1-5 ).
BB/Wor-diabetes. Spontaneously diabetic animals also displayed increased adenylate cyclase activity relative to their Wistar-derived nondiabetic controls (DB-RES). In contrast to the STZ-diabetic's, however, BB/Wor rats displayed approximately twofold increases in basal and forskolin-stimulatable adenylate cyclase. This increase accounted for the majority but not all of the increases in GTP, glucagon, fluoroaluminate, and cholera toxin-stiymulated adenylate cyclase in these rats.
In agreement with the data from the STZ-model, BB/Wordiabetics also displayed increased levels of Gs activity (Table   VI) and cholera toxin stimulated [32P]ADP ribosylation of the 43 and 47.5 kD liver membrane peptides, which are thought to represent the a-subunits of Gs (Fig. 8) . There was also an increase in these subunits when measured immunologically using antiserum against the COOH-terminal decapeptide of Gm, (Fig. 1 1) .
We also observed a 40% decrease in the IAP-stimulated
[32P]ADP-ribosylation of Gi in BB/Wor-diabetics. In contrast, no decrease in Gia could be detected by immunological means using antisera to the COOH-terminal decapeptides of ai-3 and aT (Fig. 11 ). This suggests that there is no change in the amount ofGia but that its susceptibility to ADP-ribosylation is changed. This may indicate altered association between the various subunits of heterotrimeric Gi in this naturally occurring model of acute type I diabetes mellitus. Alternatively, there may be a decrease in another G protein which does not cross-react with the antisera, but can be ADP-ribosylated by the toxin.
Pobiner et al. (46) have reported that rat liver contains "spare" Gi, i.e., > 80% of Gi has to be modified before IAP affects angiotensin II inhibition ofadenylate cyclase (46) . Thus a 40% decrease in Gi in the livers of BB/Wor spontaneous diabetic rats, if it occurs, would not modify angiotensin II inhibition of hepatic cAMP content and membrane adenylate cyclase activity. In summary, while an increase in adenylate cyclase per se seems to be the major contributor to increases in GTP-, glucagon-, fluoroaluminate-, and cholera toxin-stimulated adenylate cyclase activity in the livers of STZ and BB/Wor rats, it appears likely that the change in G5-activity is responsible for part of the increase. In contrast, there is no change in Gi in the STZ rat and the decrease in BB/Wor Gi, if it occurs, is not sufficient to be physiologically relevant. With respect to the increase in hepatic cAMP observed in experimental diabetes (3) (4) (5) , it should be recognized that decreased cAMP phosphodiesterase may also contribute (5) . The livers of BB/Wor rats also have elevated cAMP levels (6), but it is not known whether or not the phosphodiesterase is changed.
The alterations in molecular components of the adenylate cyclase system in the livers of diabetic rats raise a number of interesting issues. The first is the mechanism(s) by which the changes occur, i.e., the site at which insulin controls the expression of these proteins. The second is whether or not these components are altered in other tissues in diabetes, e.g., adipose tissue. The third is the possible relationship between the increased responsiveness ofadenylate cyclase to glucagon (and other agonists) and the metabolic dysfunctions of diabetes, e.g., enhanced lipolysis and gluconeogenesis. All ofthese issues represent interesting areas for future research.
